Fellows Kelly, Stoneking Colin J, Ramanathan Murali
Department of Pharmaceutical Sciences and Neurology, State University of New York, 355 Kapoor Hall, Buffalo, NY, 14214-8033, USA.
Seminar for Statistics, Department of Mathematics, ETH Zurich, Zurich, Switzerland.
J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):515-25. doi: 10.1007/s10928-015-9439-8. Epub 2015 Aug 29.
Adherence is a frequent contributing factor to variations in drug concentrations and efficacy. The purpose of this work was to develop an integrated population model to describe variation in adherence, dose-timing deviations, overdosing and persistence to dosing regimens. The hybrid Markov chain-von Mises method for modeling adherence in individual subjects was extended to the population setting using a Bayesian approach. Four integrated population models for overall adherence, the two-state Markov chain transition parameters, dose-timing deviations, overdosing and persistence were formulated and critically compared. The Markov chain-Monte Carlo algorithm was used for identifying distribution parameters and for simulations. The model was challenged with medication event monitoring system data for 207 hypertension patients. The four Bayesian models demonstrated good mixing and convergence characteristics. The distributions of adherence, dose-timing deviations, overdosing and persistence were markedly non-normal and diverse. The models varied in complexity and the method used to incorporate inter-dependence with the preceding dose in the two-state Markov chain. The model that incorporated a cooperativity term for inter-dependence and a hyperbolic parameterization of the transition matrix probabilities was identified as the preferred model over the alternatives. The simulated probability densities from the model satisfactorily fit the observed probability distributions of adherence, dose-timing deviations, overdosing and persistence parameters in the sample patients. The model also adequately described the median and observed quartiles for these parameters. The Bayesian model for adherence provides a parsimonious, yet integrated, description of adherence in populations. It may find potential applications in clinical trial simulations and pharmacokinetic-pharmacodynamic modeling.
依从性是导致药物浓度和疗效出现差异的常见因素。本研究的目的是开发一个综合人群模型,以描述依从性、给药时间偏差、用药过量和给药方案持续性的变化情况。采用贝叶斯方法,将用于个体受试者依从性建模的混合马尔可夫链 - 冯·米塞斯方法扩展到人群层面。构建并严格比较了四个关于总体依从性、两状态马尔可夫链转移参数、给药时间偏差、用药过量和持续性的综合人群模型。使用马尔可夫链 - 蒙特卡罗算法来确定分布参数并进行模拟。该模型用207名高血压患者的用药事件监测系统数据进行验证。这四个贝叶斯模型展现出良好的混合和收敛特性。依从性、给药时间偏差、用药过量和持续性分布明显非正态且多样。这些模型在复杂性以及在两状态马尔可夫链中纳入与前一次给药相互依存关系的方法上存在差异。在替代模型中,将相互依存的协同项和转移矩阵概率的双曲线参数化纳入的模型被确定为首选模型。该模型模拟的概率密度令人满意地拟合了样本患者中依从性、给药时间偏差、用药过量和持续性参数的观察概率分布。该模型还充分描述了这些参数的中位数和观察到的四分位数。用于依从性的贝叶斯模型为人群中的依从性提供了一个简洁但综合的描述。它可能在临床试验模拟和药代动力学 - 药效学建模中找到潜在应用。